ORYZF OTC

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company dedicated to advancing epigenetics-based therapies for individuals battling cancer and central nervous system (CNS) conditions. The company's clinical pipeline features two key compounds. Iadademstat (ORY-1001), a selective LSD1 inhibitor, is currently undergoing Phase II trials for various oncological indications. Similarly, vafidemstat (ORY-2001), another LSD1 inhibitor specifically designed for CNS applications, is also in Phase II for the treatment of neurological and psychiatric illnesses. Furthermore, ORY-3001, an LSD1 inhibitor, is progressing through preclinical development with the aim of addressing non-cancerous diseases. Established in 2000, Oryzon Genomics is headquartered in Cornellà de Llobregat, Spain.